Advertisment

Revolutionizing Melanoma Treatment: Quest Diagnostics Launches MelaNodal Predict

author-image
Anthony Raphael
New Update
NULL

Revolutionizing Melanoma Treatment: Quest Diagnostics Launches MelaNodal Predict

Advertisment

Quest Diagnostics, a leading provider of diagnostic information services, has made a significant contribution to the field of melanoma treatment with the launch of MelaNodal Predict. This innovative gene expression test provides individualized risk assessments of nodal metastasis for patients with melanoma, the deadliest form of skin cancer. Incorporating a combination of patient age, tumor thickness, and gene expression profiling, the test is designed to aid in treatment decisions and potentially avoid invasive surgeries.

Advertisment

MelaNodal Predict: A New Approach to Melanoma Diagnosis

Developed by Quest Diagnostics in collaboration with SkylineDx, MelaNodal Predict is a lab-developed test that examines the original diagnostic tumor biopsy of a patient. It then applies an algorithm to discern whether a patient is at low or high risk of nodal metastasis. Patients classified as low risk by the test have a survival rate of over 90 percent, offering a new level of hope for those diagnosed with this aggressive form of skin cancer. This breakthrough test is now available for dermatologists and other care providers to order from Quest Diagnostics and Dermpath Diagnostics.

Reducing the Need for Invasive Surgeries

Advertisment

In addition to aiding in the decision-making process, MelaNodal Predict also holds the potential to reduce the need for sentinel lymph node biopsies (SLNB)—a costly and invasive surgical procedure. By identifying patients who are at less risk of metastasis, providers can potentially avoid unnecessary SLNB interventions, thereby more effectively utilizing healthcare resources and managing patient risk.

Delivering Long-term Outcome Insights

MelaNodal Predict goes beyond assessing immediate risk—it also provides valuable insights into a patient's long-term outcome. This is particularly crucial for melanoma patients, as understanding their prognosis can help shape their treatment and management plans. The test's ability to predict better survival rates for low-risk patients offers a new level of reassurance and a clearer path towards personalized care.

Advertisment

Continued Innovation in the Oncology Space

The launch of MelaNodal Predict is part of Quest Diagnostics' ongoing commitment to innovation in the oncology space. The company has been focusing on high growth within its highly specialized advanced diagnostics offering, with recent strategic acquisitions and collaborations. The global melanoma therapeutics market was valued at 5.5 billion in 2022 and is projected to witness a compound annual growth rate (CAGR) of 10.3 percent by 2032. With the introduction of MelaNodal Predict, Quest Diagnostics continues to pave the way for advancements in the field of molecular diagnostics and personalized melanoma care.

Looking Ahead: A Future of Personalized Healthcare

The introduction of MelaNodal Predict is a step towards a future where healthcare is more accurate, personalized, and effective. The use of artificial intelligence in disease risk prediction, such as the Bi-LSTM smart healthcare system and combined PRSs, suggests a future where risk prediction and treatment decisions are more precise and tailored to the individual patient's needs. With MelaNodal Predict, Quest Diagnostics is not only advancing melanoma treatment but also contributing to the broader evolution of personalized healthcare.

Advertisment
Chat with Dr. Medriva !